|
1
|
Klein MJ and Siegal GP: Osteosarcoma:
Anatomic and histologic variants. Am J Clin Pathol. 125:555–581.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Stiller CA, Desandes E, Danon SE,
Izarzugaza I, Ratiu A, Vassileva-Valerianova Z and
Steliarova-Foucher E: Cancer incidence and survival in European
adolescents (1978–1997)-report from the automated childhood cancer
information system project. Eur J Cancer. 42:2006–2018. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Nie Z and Peng H: Osteosarcoma in patients
below 25 years of age-An observational study of incidence,
metastasis, treatment and outcomes. Oncol Lett. 16:6502–6514.
2018.PubMed/NCBI
|
|
4
|
Ottaviani G and Jaffe N: The epidemiology
of osteosarcoma. Cancer Treat Res. 152:3–13. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Geller DS and Gorlick R: Osteosarcoma: A
review of diagnosis, management, and treatment strategies. Clin Adv
Hematol Oncol. 8:705–718. 2010.PubMed/NCBI
|
|
6
|
Morrow JJ and Khanna C: Osteosarcoma
genetics and epigenetics: Emerging biology and candidate therapies.
Crit Rev Oncog. 20:173–197. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Rao-Bindal K and Kleinerman ES: Epigenetic
regulation of apoptosis and cell cycle in osteosarcoma. Sarcoma.
2011:6794572011. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Mutsaers AJ and Walkley CR: Cells of
origin in osteosarcoma: Mesenchymal stem cells or osteoblast
committed cells? Bone. 62:56–63. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Zheng Y, Wang G, Chen R, Hua Y and Cai Z:
Mesenchymal stem cells in the osteosarcoma microenvironment-their
biological properties, influence on tumor growth, and therapeutic
implications. Stem Cell Res Ther. 9:222018. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Alfranca A, Martinez-Cruzado L, Tornin J,
Abarrategi A, Amaral T, de Alava E, Menendez P, Garcia-Castro J and
Rodriguez R: Bone microenvironment signals in osteosarcoma
development. Cell Mol Life Sci. 72:3097–3113. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Velletri T, Xie N, Wang Y, Huang Y, Yang
Q, Chen X, Chen Q, Shou P, Gan Y, Cao G, et al: P53 functional
abnormality in mesenchymal stem cells promotes osteosarcoma
development. Cell Death Dis. 7:e20152016. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Han Y, Kim YM, Kim HS and Lee KY:
Melatonin promotes osteoblast differentiation by regulating Osterix
protein stability and expression. Sci Rep. 7:57162017. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Komori T: Runx2, an inducer of osteoblast
and chondrocyte differentiation. Histochem Cell Biol. 149:313–323.
2018. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Shin MH, He Y, Marrogi E, Piperdi S, Ren
L, Khanna C, Gorlick R, Liu C and Huang J: A RUNX2-mediated
epigenetic regulation of the survival of p53 defective cancer
cells. PLoS Genet. 12:e10058842016. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Martin JW, Zielenska M, Stein GS, van
Wijnen AJ and Squire JA: The role of RUNX2 in osteosarcoma
oncogenesis. Sarcoma. 2011:2827452011. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Molchadsky A, Shats I, Goldfinger N,
Pevsner-Fischer M, Olson M, Rinon A, Tzahor E, Lozano Gina G,
Zipori D, Sarlig R and Rotter V: p53 plays a role in mesenchymal
differentiation programs, in a cell fate dependent manner. PLoS
One. 3:e37072008. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Tang N, Song WX, Luo J, Haydon RC and He
TC: Osteosarcoma development and stem cell differentiation. Clin
Orthop Relat Res. 466:2114–2130. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Martin JW, Squire JA and Zielenska M: The
genetics of osteosarcoma. Sarcoma. 2012:6272542012. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Sharma S, Kelly TK and Jones PA:
Epigenetics in cancer. Carcinogenesis. 31:27–36. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Jones KB, Salah Z, Del Mare S, Galasso M,
Gaudio E, Nuovo GJ, Lovat F, LeBlanc K, Palatini J, Randall RL, et
al: MicroRNA signatures associate with pathogenesis and progression
of osteosarcoma. Cancer Res. 72:1865–1877. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Li Y, Meng G, Huang L and Guo QN:
Hypomethylation of the P3 promoter is associated with up-regulation
of IGF2 expression in human osteosarcoma. Hum Pathol. 40:1441–1447.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Lu J and Wang J: IRX1 hypomethylation in
osteosarcoma metastasis. Oncotarget. 6:16802–16803. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Lopes-Júnior LC, Silveira DSC, Vulczak A,
Santos JC, Veronez LC, Fisch A, Flória-Santos M, Lima RAG and
Pereira-da-Silva G: Emerging cytokine networks in osteosarcoma.
Oncol Commun. 2:e11672016.
|
|
24
|
Yang Y, Yang R, Roth M, Piperdi S, Zhang
W, Dorfman H, Rao P, Park A, Tripathi S, Freeman C, et al:
Genetically transforming human osteoblasts to sarcoma: Development
of an osteosarcoma model. Genes Cancer. 8:484–494. 2017.PubMed/NCBI
|
|
25
|
Broadhead ML, Clark JCM, Myers DE, Dass CR
and Choong PFM: The molecular pathogenesis of osteosarcoma: A
review. Sarcoma. 2011:9592482011. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Denduluri SK, Wang Z, Yan Z, Wang J, Wei
Q, Mohammed MK, Haydon RC, Luu HH and He TC: Molecular pathogenesis
and therapeutic strategies of human osteosarcoma. J Biomed Res.
30:5–18. 2016.
|
|
27
|
Deng ZL, Sharff KA, Tang N, Song WX, Luo
J, Luo X, Chen J, Bennett E, Reid R, Manning D, et al: Regulation
of osteogenic differentiation during skeletal development. Front
Biosci. 13:2001–2021. 2008. View
Article : Google Scholar : PubMed/NCBI
|
|
28
|
Tu B, Peng ZX, Fan QM, Du L, Yan W and
Tang TT: Osteosarcoma cells promote the production of pro-tumor
cytokines in mesenchymal stem cells by inhibiting their osteogenic
differentiation through the TGF-β/Smad2/3 pathway. Exp Cell Res.
320:164–173. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Mori T, Sato Y, Miyamoto K, Kobayashi T,
Shimizu T, Kanagawa H, Katsuyama E, Fujie A, Hao W, Tando T, et al:
TNFα promotes osteosarcoma progression by maintaining tumor cells
in an undifferentiated state. Oncogene. 33:4236–4246. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Hanahan D and Weinberg RA: Hallmarks of
cancer: The next generation. Cell. 144:646–674. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Tung PY and Knoepfler PS: Epigenetic
mechanisms of tumorigenicity manifesting in stem cells. Oncogene.
34:2288–2296. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Klimczak A and Kozlowska U: Mesenchymal
stromal cells and tissue-specific progenitor cells: their role in
tissue homeostasis. Stem Cells Int. 2016:42852152016. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Mohseny AB, Szuhai K, Romeo S, Buddingh
EP, Briaire-de Bruijn I, de Jong D, van Pel M, Cleton-Jansen AM and
Hogendoorn PC: Osteosarcoma originates from mesenchymal stem cells
in consequence of aneuploidization and genomic loss of Cdkn2. J
Pathol. 219:294–305. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Zhang D and Liu S: SOX5 promotes
epithelial-mesenchymal transition in osteosarcoma via regulation of
Snail. J BUON. 22:258–264. 2017.PubMed/NCBI
|
|
35
|
Mannerström B, Kornilov R, Abu-Shahba AG,
Chowdhury IM, Sinha S, Seppänen-Kaijansinkko R and Kaur S:
Epigenetic alterations in mesenchymal stem cells by
osteosarcoma-derived extracellular vesicles. Epigenetics.
14:352–364. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Chen Z, Guo J, Zhang K and Guo Y: TP53
mutations and survival in osteosarcoma patients: A meta-analysis of
published data. Dis Markers. 2016:46395752016. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Perry JA, Kiezun A, Tonzi P, Van Allen EM,
Carter SL, Baca SC, Cowley GS, Bhatt AS, Rheinbay E, Pedamallu CS,
et al: Complementary genomic approaches highlight the PI3K/mTOR
pathway as a common vulnerability in osteosarcoma. Proc Natl Acad
Sci USA. 111:E5564–E5573. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Kovac M, Blattmann C, Ribi S, Smida J,
Mueller NS, Engert F, Castro-Giner F, Weischenfeldt J, Kovacova M,
Krieg A, et al: Exome sequencing of osteosarcoma reveals mutation
signatures reminiscent of BRCA deficiency. Nat Commun. 6:89402015.
View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Wang D, Niu X, Wang Z, Song CL, Huang Z,
Chen KN, Duan J, Bai H, Xu J, Zhao J, et al: Multiregion sequencing
reveals the genetic heterogeneity and evolutionary history of
osteosarcoma and matched pulmonary metastases. Cancer Res. 79:7–20.
2019. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Lin PP, Pandey MK, Jin F, Raymond AK,
Akiyama H and Lozano G: Targeted mutation of p53 and Rb in
mesenchymal cells of the limb bud produces sarcomas in mice.
Carcinogenesis. 30:1789–1795. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Rutkovskiy A, Stensløkken Ko and Vaage IJ:
Osteoblast differentiation at a glance. Med Sci Monit Basic Res.
22:95–106. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Long F: Building strong bones: Molecular
regulation of the osteoblast lineage. Nat Rev Mol Cell Biol.
13:27–38. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Techavichit P, Gao Y, Kurenbekova L, Shuck
R, Donehower LA and Yustein JT: Secreted Frizzled-Related Protein 2
(sFRP2) promotes osteosarcoma invasion and metastatic potential.
BMC Cancer. 16:8692016. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Kim H, Yoo S, Zhou R, Xu A, Bernitz JM,
Yuan Y, Gomes AM, Daniel MG, Su J, Demicco EG, et al: Oncogenic
role of SFRP2 in p53-mutant osteosarcoma development via autocrine
and paracrine mechanism. Proc Natl Acad Sci USA. 115:E11128–E11137.
2018. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Chen KS, Kwon WS, Kim J, Heo SJ, Kim HS,
Kim HK, Kim SH, Lee WS, Chung HC, Rha SY and Hwang TH: A novel
TP53-KPNA3 translocation defines a de novo treatment-resistant
clone in osteosarcoma. Cold Spring Harb Mol Case Stud.
2:a0009922016. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Del Mare S, Kurek KC, Stein GS, Lian JB
and Aqeilan RI: Role of the WWOX tumor suppressor gene in bone
homeostasis and the pathogenesis of osteosarcoma. Am J Cancer Res.
1:585–594. 2011.PubMed/NCBI
|
|
47
|
Del Mare S and Aqeilan RI: Tumor
Suppressor WWOX inhibits osteosarcoma metastasis by modulating
RUNX2 function. Sci Rep. 5:129592015. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Henley SA and Dick FA: The retinoblastoma
family of proteins and their regulatory functions in the mammalian
cell division cycle. Cell Div. 7:102012. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Abreu Velez AM and Howard MS:
Tumor-suppressor genes, cell cycle regulatory checkpoints, and the
skin. N Am J Med Sci. 7:176–188. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Min EY, Kim IH, Lee J, Kim EY, Choi YH and
Nam TJ: The effects of fucodian on senescence are controlled by the
p16INK4a-pRb and p14Arf-p53 pathways in hepatocellular carcinoma
and hepatic cell lines. Int J Oncol. 45:47–56. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Shi D and Gu W: Dual roles of MDM2 in the
regulation of p53: Ubiquitination dependent and ubiquitination
independent mechanisms of MDM2 repression of p53 activity. Genes
Cancer. 3:240–248. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Zhang H, Mao JS and Hu WF: Functional
genetic single-nucleotide polymorphisms (SNPs) in cyclin-dependent
kinase inhibitor 2A/B (CDKN2A/B) locus are associated with risk and
prognosis of osteosarcoma in chinese populations. Med Sci Monit.
25:1307–1313. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Zhao Y, Yu H and Hu W: The regulation of
MDM2 oncogene and its impact on human cancers. Acta Biochim Biophys
Sin (Shanghai). 46:180–189. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Yu Q, Li Y, Mu K, Li Z, Meng Q, Wu X, Wang
Y and Li L: Amplification of Mdmx and overexpression of MDM2
contribute to mammary carcinogenesis by substituting for p53
mutations. Diagn Pathol. 9:712014. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Han G, Wang Y and Bi W: C-Myc
overexpression promotes osteosarcoma cell invasion via activation
of MEK-ERK pathway. Oncol Res. 20:149–156. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Wu X, Cai ZD, Lou LM and Zhu YB:
Expressions of p53, c-Myc, Bcl-2 and apoptotic index in human
osteosarcoma and their correlations with prognosis of patients.
Cancer Epidemiol. 36:212–216. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Chen D, Zhao Z, Huang Z, Chen DC, Zhu XX,
Wang YZ, Yan YW, Tang S, Madhavan S, Ni W, et al: Super enhancer
inhibitors suppress MYC driven transcriptional amplification and
tumor progression in osteosarcoma. Bone Res. 6:112018. View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Wang Q, Liu H, Wang Q, Zhou F, Liu Y,
Zhang Y, Ding H, Yuan M, Li F and Chen Y: Involvement of c-Fos in
cell proliferation, migration, and invasion in osteosarcoma cells
accompanied by altered expression of Wnt2 and Fzd9. PLoS One.
12:e01805582017. View Article : Google Scholar : PubMed/NCBI
|
|
59
|
Xu G, Guo Y, Xu D, Wang Y, Shen Y, Wang F,
Lv Y, Song F, Jiang D, Zhang Y, et al: TRIM14 regulates cell
proliferation and invasion in osteosarcoma via promotion of the AKT
signaling pathway. Sci Rep. 7:424112017. View Article : Google Scholar : PubMed/NCBI
|
|
60
|
Nowacka-Zawisza M and Wiśnik E: DNA
methylation and histone modifications as epigenetic regulation in
prostate cancer. Oncol Rep. 38:2587–2596. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
61
|
Shanmugam MK, Arfuso F, Arumugam S,
Chinnathambi A, Jinsong B, Warrier S, Wang LZ, Kumar AP, Ahn KS,
Sethi G, et al: Role of novel histone modifications in cancer.
Oncotarget. 9:11414–11426. 2017.PubMed/NCBI
|
|
62
|
Sachdeva M, Dodd RD, Huang Z, Grenier C,
Ma Y, Lev DC, Cardona DM, Murphy SK and Kirsch DG: Epigenetic
silencing of Kruppel like factor-3 increases expression of
pro-metastatic miR-182. Cancer Lett. 369:202–211. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
63
|
Kanherkar RR, Bhatia-Dey N and Csoka AB:
Epigenetics across the human lifespan. Front Cell Dev Biol.
2:492014. View Article : Google Scholar : PubMed/NCBI
|
|
64
|
Sadikovic B, Yoshimoto M, Al-Romaih K,
Maire G, Zielenska M and Squire JA: In vitro analysis of integrated
global high-resolution DNA methylation profiling with genomic
imbalance and gene expression in osteosarcoma. PLoS One.
3:e28342008. View Article : Google Scholar : PubMed/NCBI
|
|
65
|
Kresse SH, Rydbeck H, Skårn M, Namløs HM,
Barragan-Polania AH, Cleton-Jansen AM, Serra M, Liestøl K,
Hogendoorn PC, Hovig E, et al: Integrative analysis reveals
relationships of genetic and epigenetic alterations in
osteosarcoma. PLoS ONE. 7:e482622012. View Article : Google Scholar : PubMed/NCBI
|
|
66
|
Rosenblum JM, Wijetunga NA, Fazzari MJ,
Krailo M, Barkauskas DA, Gorlick R and Greally JM: Predictive
properties of DNA methylation patterns in primary tumor samples for
osteosarcoma relapse status. Epigenetics. 10:31–39. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
67
|
Varshney J, Scott MC, Largaespada DA and
Subramanian S: Understanding the osteosarcoma pathobiology-a
comparative oncology approach. Vet Sci. 3(pii): E32016. View Article : Google Scholar : PubMed/NCBI
|
|
68
|
Jeziorska DM, Murray RJS, De Gobbi M,
Gaentzsch R, Garrick D, Ayyub H, Chen T, Li E, Telenius J, Lynch M,
et al: DNA methylation of intragenic CpG islands depends on their
transcriptional activity during differentiation and disease. Proc
Natl Acad Sci USA. 114:E7526–E7535. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
69
|
Li B and Ye Z: Epigenetic alterations in
osteosarcoma: Promising targets. Mol Biol Rep. 41:3303–3315. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
70
|
Hamidi T, Singh AK and Chen T: Genetic
alterations of DNA methylation machinery in human diseases.
Epigenomics. 7:247–265. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
71
|
Li E and Zhang Y: DNA methylation in
mammals. Cold Spring Harb Perspect Biol. 6:a0191332014. View Article : Google Scholar : PubMed/NCBI
|
|
72
|
Goll MG, Kirpekar F, Maggert KA, Yoder JA,
Hsieh CL, Zhang X, Golic KG, Jacobsen SE and Bestor TH: Methylation
of tRNA Asp by the DNA methyltransferase homolog Dnmt2. Science.
311:395–398. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
73
|
Pfeifer GP: Defining driver DNA
methylation changes in human cancer. Int J Mol Sci. 19(pii):
E11662018. View Article : Google Scholar : PubMed/NCBI
|
|
74
|
Al-Romaih K, Sadikovic B, Yoshimoto M,
Wang Y, Zielenska M and Squire JA: Decitabine-induced demethylation
of 5′ CpG island in GADD45A leads to apoptosis in osteosarcoma
cells. Neoplasia. 10:471–480. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
75
|
Amente S, Zhang J, Lavadera ML, Lania L,
Avvedimento EV and Majello B: Myc and PI3K/AKT signaling
cooperatively repress FOXO3a-dependent PUMA and GADD45a gene
expression. Nucleic Acids Res. 39:9498–9507. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
76
|
Zhang H, He J, Li J, Tian D, Gu L and Zhou
M: Methylation of RASSF1A gene promoter is regulated by p53 and
DAXX. FASEB J. 27:232–242. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
77
|
Song MS, Song SJ, Kim SY, Oh HJ and Lim
DS: The tumour suppressor RASSF1A promotes MDM2 self-ubiquitination
by disrupting the MDM2-DAXX-HAUSP complex. EMBO J. 27:1863–1874.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
78
|
Guo X, Liu W, Pan Y, Ni P, Ji J, Guo L,
Zhang J, Wu J, Jiang J, Chen X, et al: Homeobox gene IRX1 is a
tumor suppressor gene in gastric carcinoma. Oncogene. 29:3908–3920.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
79
|
Moriarity BS, Otto GM, Rahrmann EP, Rathe
SK, Wolf NK, Weg MT, Manlove LA, LaRue RS, Temiz NA, Molyneux SD,
et al: A sleeping beauty forward genetic screen identifies new
genes and pathways driving osteosarcoma development and metastasis.
Nat Genet. 47:615–624. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
80
|
Xu J, Li D, Cai Z, Zhang Y, Huang Y, Su B
and Ma R: An integrative analysis of DNA methylation in
osteosarcoma. J Bone Oncol. 9:34–40. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
81
|
Li X, Lu H, Fan G, He M, Sun Y, Xu K and
Shi F: A novel interplay between HOTAIR and DNA methylation in
osteosarcoma cells indicates a new therapeutic strategy. J Cancer
Res Clin Oncol. 143:2189–2200. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
82
|
Wang Q: CpG methylation patterns are
associated with gene expression variation in osteosarcoma. Mol Med
Rep. 16:901–907. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
83
|
Li Q, Li H, Zhao X, Wang B, Zhang L, Zhang
C and Zhang F: DNA methylation mediated downregulation of miR-449c
controls osteosarcoma cell cycle progression by directly targeting
oncogene c-Myc. Int J Biol Sci. 13:1038–1050. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
84
|
Tian W, Li Y, Zhang J, Li J and Gao J:
Combined analysis of DNA methylation and gene expression profiles
of osteosarcoma identified several prognosis signatures. Gene.
650:7–14. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
85
|
Bannister AJ and Kouzarides T: Regulation
of chromatin by histone modifications. Cell Res. 21:381–395. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
86
|
Li S: Implication of posttranslational
histone modifications in nucleotide excision repair. Int J Mol Sci.
13:12461–12486. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
87
|
Kelly TK, De Carvalho DD and Jones PA:
Epigenetic modifications as therapeutic targets. Nat Biotechnol.
28:1069–1078. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
88
|
Ropero S and Esteller M: The role of
histone deacetylases (HDACs) in human cancer. Mol Oncol. 1:19–25.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
89
|
Black JC, Van Rechem C and Whetstine JR:
Histone lysine methylation dynamics: Establishment, regulation, and
biological impact. Mol Cell. 48:491–507. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
90
|
Vaidya H, Rumph C and Katula KS:
Inactivation of the WNT5A alternative promoter B is associated with
DNA methylation and histone modification in osteosarcoma cell lines
U2OS and SaOS-2. PLoS One. 11:e01513922016. View Article : Google Scholar : PubMed/NCBI
|
|
91
|
He C, Sun J, Liu C, Jiang Y and Hao Y:
Elevated H3K27me3 levels sensitize osteosarcoma to cisplatin. Clin
Epigenetics. 11:82019. View Article : Google Scholar : PubMed/NCBI
|
|
92
|
Lawlor ER and Thiele CJ: pigenetic changes
in pediatric solid tumors: Promising new targets. Clin Cancer Res.
18:2768–2779. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
93
|
Wu SC and Benavente CA: Chromatin
remodeling protein HELLS is upregulated by inactivation of the
RB-E2F pathway and is nonessential for osteosarcoma tumorigenesis.
Oncotarget. 9:32580–32592. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
94
|
Nie JH, Li TX, Zhang XQ and Liu J: Roles
of non-coding RNAs in normal human brain development, brain tumor,
and neuropsychiatric disorders. Noncoding RNA. 5(pii):
E362019.PubMed/NCBI
|
|
95
|
Fernandes JCR, Acuña SM, Aoki JI,
Floeter-Winter LM and Muxel SM: Long non-coding RNAs in the
regulation of gene expression: Physiology and disease. Noncoding
RNA. 5(pii): E172019.PubMed/NCBI
|
|
96
|
Calin GA: The noncoding RNA
revolution-three decades and still going strong! Mol Oncol.
13(3)2019.
|
|
97
|
Patil VS, Zhou R and Rana TM: Gene
regulation by non-coding RNAs. Crit Rev Biochem Mol Biol. 49:16–32.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
98
|
Mens MMJ and Ghanbari M: Cell cycle
regulation of stem cells by microRNAs. Stem Cell Rev Rep.
14:309–322. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
99
|
O'Brien J, Hayder H, Zayed Y and Peng C:
Overview of microRNA biogenesis, mechanisms of actions, and
circulation. Front Endocrinol (Lausanne). 9:4022018. View Article : Google Scholar : PubMed/NCBI
|
|
100
|
Li Y, Zeng C, Tu M, Jiang W, Dai Z, Hu Y,
Deng Z and Xiao W: MicroRNA-200b acts as a tumor suppressor in
osteosarcoma via targeting ZEB1. Onco Targets Ther. 9:3101–3111.
2016.PubMed/NCBI
|
|
101
|
Jiang R, Zhang C, Liu G, Gu R and Wu H:
MicroRNA-101 inhibits proliferation, migration and invasion in
osteosarcoma cells by targeting ROCK1. Am J Cancer Res. 7:88–97.
2017.PubMed/NCBI
|
|
102
|
Xu H, Liu X and Zhao J: Down-regulation of
miR-3928 promoted osteosarcoma growth. Cell Physiol Biochem.
33:1547–1556. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
103
|
Huang G, Nishimoto K, Zhou Z, Hughes D and
Kleinerman ES: miR-20a encoded by the miR-17-92 cluster increases
the metastatic potential of osteosarcoma cells by regulating Fas
expression. Cancer Res. 72:908–916. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
104
|
Xu H, Liu X, Zhou J, Chen X and Zhao J:
miR-574-3p acts as a tumor promoter in osteosarcoma by targeting
SMAD4 signaling pathway. Oncol Lett. 12:5247–5253. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
105
|
Xiao Q, Huang L, Zhang Z, Chen X, Luo J,
Zhang Z, Chen S, Shu Y, Han Z and Cao K: Overexpression of miR-140
inhibits proliferation of osteosarcoma cells via suppression of
histone deacetylase 4. Oncol Res. 25:267–275. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
106
|
Luo Z, Liu M, Zhang H and Xia Y:
Association of circulating miR-125b and survival in patients with
osteosarcoma-A single center experience. J Bone Oncol. 5:167–172.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
107
|
Qu Y, Pan S, Kang M, Dong R and Zhao J:
MicroRNA-150 functions as a tumor suppressor in osteosarcoma by
targeting IGF2BP1. Tumour Biol. 37:5275–5284. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
108
|
Ali A, Hu L, Qian A, Chen C and Yang T:
Long noncoding RNAs and human osteosarcoma. J Stem Cell Res Ther.
8:32018. View Article : Google Scholar
|
|
109
|
Guo W, Jiang H, Li H, Li F, Yu Q, Liu Y,
Jiang W and Zhang M: LncRNA-SRA1 suppresses osteosarcoma cell
proliferation while promoting cell apoptosis. Technol Cancer Res
Treat. 18:1–11. 2019. View Article : Google Scholar
|
|
110
|
Deng R, Zhang J and Chen J: lncRNA SNHG1
negatively regulates miRNA-101-3p to enhance the expression of
ROCK1 and promote cell proliferation, migration and invasion in
osteosarcoma. Int J Mol Med. 43:1157–1166. 2019.PubMed/NCBI
|
|
111
|
Zhou Y, Yin L, Li H, Liu LH and Xiao T:
The LncRNA LINC00963 facilitates osteosarcoma proliferation and
invasion by suppressing miR-204-3p/FN1 axis. Cancer Biol Ther.
20:1141–1148. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
112
|
Chen Y, Huang W, Sun W, Zheng B, Wang C,
Luo Z, Wang J and Yan W: LncRNA MALAT1 promotes cancer metastasis
in osteosarcoma via activation of the PI3K-Akt signaling pathway.
Cell Physiol Biochem. 51:1313–1326. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
113
|
Gu W, Zhang E, Song L, Tu L, Wang Z, Tian
F, Aikenmu K, Chu G and Zhao J: Long noncoding RNA HOXD-AS1
aggravates osteosarcoma carcinogenesis through epigenetically
inhibiting p57 via EZH2. Biomed Pharmacother. 106:890–895. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
114
|
Yu X, Hu L, Li S, Shen J, Wang D, Xu R and
Yang H: Long non-coding RNA Taurine upregulated gene 1 promotes
osteosarcoma cell metastasis by mediating HIF-1α via miR-143-5p.
Cell Death Dis. 10:2802019. View Article : Google Scholar : PubMed/NCBI
|
|
115
|
Kun-Peng Z, Xiao-Long M and Chun-Lin Z:
Overexpressed circPVT1, a potential new circular RNA biomarker,
contributes to doxorubicin and cisplatin resistance of osteosarcoma
cells by regulating ABCB1. Int J Biol Sci. 14:321–330. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
116
|
Vo JN, Cieslik M, Zhang Y, Shukla S, Xiao
L, Zhang Y, Wu YM, Dhanasekaran SM, Engelke CG, Cao X, et al: The
landscape of circular RNA in cancer. Cell. 176:869–881.e13. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
117
|
Wang C, Ren M, Zhao X, Wang A and Wang J:
Emerging roles of circular RNAs in osteosarcoma. Med Sci Monit.
24:7043–7050. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
118
|
Wu Y, Xie Z, Chen J, Chen J, Ni W, Ma Y,
Huang K, Wang G, Wang J, Ma J, et al: Circular RNA circTADA2A
promotes osteosarcoma progression and metastasis by sponging
miR-203a-3p and regulating CREB3 expression. Mol Cancer. 18:732019.
View Article : Google Scholar : PubMed/NCBI
|
|
119
|
Liu W, Zhang J, Zou C, Xie X, Wang Y, Wang
B, Zhao Z, Tu J, Wang X, Li H, et al: Microarray expression profile
and functional analysis of circular RNAs in osteosarcoma. Cell
Physiol Biochem. 43:969–985. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
120
|
Goldszmid RS and Trinchieri G: The price
of immunity. Nat Immunol. 13:932–938. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
121
|
Turtle CJ, Hudecek M, Jensen MC and
Riddell SR: Engineered T cells for anti-cancer therapy. Curr Opin
Immunol. 24:633–639. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
122
|
Tu B, Du L, Fan QM, Tang Z and Tang TT:
STAT3 activation by IL-6 from mesenchymal stem cells promotes the
proliferation and metastasis of osteosarcoma. Cancer Lett.
325:80–88. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
123
|
Wu Z, Yang W, Liu J and Zhang F:
Interleukin-6 upregulates SOX18 expression in osteosarcoma. Onco
Targets Ther. 10:5329–5336. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
124
|
Tzeng HE, Tsai CH, Chang ZL, Su CM, Wang
SW, Hwang WL and Tang CH: Interleukin-6 induces vascular
endothelial growth factor expression and promotes angiogenesis
through apoptosis signal-regulating kinase 1 in human osteosarcoma.
Biochem Pharmacol. 85:531–540. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
125
|
Wu Q, Zhou X, Huang D, Ji Y and Kang F:
IL-6 enhances osteocyte-mediated osteoclastogenesis by promoting
JAK2 and RANKL activity in vitro. Cell Physiol Biochem.
41:1360–1369. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
126
|
Gross AC, Cam H, Phelps DA, Saraf AJ, Bid
HK, Cam M, London CA, Winget SA, Arnold MA, Brandolini L, et al:
IL-6 and CXCL8 mediate osteosarcoma-lung interactions critical to
metastasis. JCI Insight. 3(pii): 997912018. View Article : Google Scholar : PubMed/NCBI
|
|
127
|
Zhang H, Wu H, Zheng J, Yu P, Xu L, Jiang
P, Gao J, Wang H and Zhang Y: Transforming growth factor β1 signal
is crucial for dedifferentiation of cancer cells to cancer stem
cells in osteosarcoma. Stem Cells. 31:433–446. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
128
|
Lamora A, Talbot J, Mullard M, Brounais-Le
Royer B, Redini F and Verrecchia F: TGF-β signaling in bone
remodeling and osteosarcoma progression. J Clin Med. 5(pii):
E962016. View Article : Google Scholar : PubMed/NCBI
|
|
129
|
Li F, Li S and Cheng T: TGF-β1 promotes
osteosarcoma cell migration and invasion through the
miR-143-versican pathway. Cell Physiol Biochem. 34:2169–2179. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
130
|
Verrecchia F and Rédini F: Transforming
growth factor-β signaling plays a pivotal role in the interplay
between osteosarcoma cells and their microenvironment. Front Oncol.
8:1332018. View Article : Google Scholar : PubMed/NCBI
|
|
131
|
Lebrun JJ: The dual role of TGFβ in human
cancer: From tumor suppression to cancer metastasis. ISRN Mol Biol.
2012:3814282012.PubMed/NCBI
|
|
132
|
Cantelli G, Crosas-Molist E, Georgouli M
and Sanz-Moreno V: TGFΒ-induced transcription in cancer. Semin
Cancer Biol. 42:60–69. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
133
|
Baglio SR, Lagerweij T, Pérez-Lanzón M, Ho
XD, Léveillé N, Melo SA, Cleton-Jansen AM, Jordanova ES, Roncuzzi
L, Greco M, et al: Blocking tumor-educated MSC paracrine activity
halts osteosarcoma progression. Clin Cancer Res. 23:3721–3733.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
134
|
Wang T, Wang D, Zhang L, Yang P, Wang J,
Liu Q, Yan F and Lin F: The TGFβ-miR-499a-SHKBP1 pathway induces
resistance to EGFR inhibitors in osteosarcoma cancer stem cell-like
cells. J Exp Clin Cancer Res. 38:2262019. View Article : Google Scholar : PubMed/NCBI
|
|
135
|
Kato H, Wakabayashi H, Naito Y, Kato S,
Nakagawa T, Matsumine A and Sudo A: Anti-tumor necrosis factor
therapy inhibits lung metastasis in an osteosarcoma cell line.
Oncology. 88:139–146. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
136
|
Ishikawa T, Shimizu T, Ueki A, Yamaguchi
SI, Onishi N, Sugihara E, Kuninaka S, Miyamoto T, Morioka H,
Nakayama R, et al: Twist2 functions as a tumor suppressor in murine
osteosarcoma cells. Cancer Sci. 104:880–888. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
137
|
Lin H, Lee E, Hestir K, Leo C, Huang M,
Bosch E, Halenbeck R, Wu G, Zhou A, Behrens D, et al: Discovery of
a cytokine and its receptor by functional screening of the
extracellular proteome. Science. 320:807–811. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
138
|
Wang Y, Szretter KJ, Vermi W, Gilfillan S,
Rossini C, Cella M, Barrow AD, Diamond MS and Colonna M: IL-34 is a
tissue-restricted ligand of CSF1R required for the development of
Langerhans cells and microglia. Nat Immunol. 13:753–760. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
139
|
Foucher ED, Blanchard S, Preisser L, Garo
E, Ifrah N, Guardiola P, Delneste Y and Jeannin P: IL-34 induces
the differentiation of human monocytes into immunosuppressive
macrophages-Antagonistic effects of GM-CSF and IFNγ. PLoS One.
8:e560452013. View Article : Google Scholar : PubMed/NCBI
|
|
140
|
Ségaliny AI, Mohamadi A, Dizier B,
Lokajczyk A, Brion R, Lanel R, Amiaud J, Charrier C, Boisson-Vidal
C and Heymann D: Interleukin-34 promotes tumor progression and
metastatic process in osteosarcoma through induction of
angiogenesis and macrophage recruitment. Int J Cancer. 137:73–85.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
141
|
Honorati MC, Cattini L and Facchini A:
Possible prognostic role of IL-17R in osteosarcoma. J Cancer Res
Clin Oncol. 133:1017–1021. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
142
|
Wang M, Wang L, Ren T, Xu L and Wen Z:
IL-17A/IL-17RA interaction promoted metastasis of osteosarcoma
cells. Cancer Biol Ther. 14:155–163. 2013. View Article : Google Scholar : PubMed/NCBI
|
